Drugs / 124I-MIBG
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT01583842 | Apr 2013 → Feb 2021 | neuroblastoma | Miguel Pampaloni | Terminated | No outcome recorded Stop: Business |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 124I-MIBG | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01583842 ↗ |
| Known as | 124I-Metaiodobenzylguanidine | “124I-Metaiodobenzylguanidine (MIBG) (no-carrier added)” NCT01583842 ↗ |
| Modality | Diagnostic / imaging agent | “diagnostic imaging dose of 124I-MIBG” NCT01583842 ↗ |